Roszdravnadzor has given out the first license for the production of biomedical cell products. The recipient became one of the Russian pharmaceutical companies, said the health Ministry.
Biomedical cellular products (BMCP) is cultured human cells, these drugs are widely used in regenerative medicine.
The therapeutic properties of this product are in the process of working with biological material obtained from the patient or a donor.
So, with autologous products can be obtained BMKP used in the treatment of diseases of musculoskeletal apparatus (e.g., restoration of damages of the cartilage surface of the joint), ophthalmology (recovery of the cornea), cancer and other diseases, which can significantly reduce disability.
“Allogeneic products are widely investigated and applied in the world for the treatment of systemic diseases, such as osteoarthritis, cardiovascular disease, gastrointestinal disease and severe life-threatening conditions, such as acute myocardial infarction or acute respiratory distress syndrome, which is one of the main complications in severe COVID-19, which is especially important at the moment”, – stressed in the Ministry of health.